BofA lowered the firm’s price target on Chemed (CHE) to $595 from $610 and keeps a Buy rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Chemed management to meet with Oppenheimer
- Chemed upgraded to Buy from Hold at Jefferies
- Optimistic Outlook for Chemed: Buy Rating Supported by Favorable Medicare Rates and Strategic Share Repurchases
- Chemed board authorizes additional $300M for stock repurchases
- Chemed board declares increased quarterly dividend of 60c per share